{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,29]],"date-time":"2025-08-29T10:46:47Z","timestamp":1756464407020,"version":"3.37.3"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2023,2,25]],"date-time":"2023-02-25T00:00:00Z","timestamp":1677283200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2023,2,25]],"date-time":"2023-02-25T00:00:00Z","timestamp":1677283200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100004312","name":"Eli Lilly and Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004312","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Drug Investig"],"published-print":{"date-parts":[[2023,3]]},"DOI":"10.1007\/s40261-022-01240-9","type":"journal-article","created":{"date-parts":[[2023,2,25]],"date-time":"2023-02-25T13:03:37Z","timestamp":1677330217000},"page":"185-196","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Comparison of Real-World Costs, Healthcare Resource Utilization, and Comorbidity-Related Costs Between Ixekizumab and Secukinumab Among Biologic-Experienced Patients with Psoriasis Over 18 Months in the USA"],"prefix":"10.1007","volume":"43","author":[{"given":"Andrew","family":"Blauvelt","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nianwen","family":"Shi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Najwa","family":"Somani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Russel","family":"Burge","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Baojin","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Terri","family":"Ridenour","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Scott","family":"Kern","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carolyn","family":"Lew","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicole","family":"Zimmerman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mwangi","family":"Murage","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,2,25]]},"reference":[{"issue":"9997","key":"1240_CR1","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1016\/S0140-6736(14)61909-7","volume":"386","author":"W-H Boehncke","year":"2015","unstructured":"Boehncke W-H, Sch\u00f6n MP. Psoriasis. Lancet. 2015;386(9997):983\u201394.","journal-title":"Lancet"},{"issue":"3","key":"1240_CR2","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1016\/j.jaad.2013.11.013","volume":"70","author":"TD Rachakonda","year":"2014","unstructured":"Rachakonda TD, Schupp CW, Armstrong AW. Psoriasis prevalence among adults in the United States. J Am Acad Dermatol. 2014;70(3):512\u20136.","journal-title":"J Am Acad Dermatol"},{"issue":"6","key":"1240_CR3","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1001\/jamadermatol.2014.3593","volume":"151","author":"EA Brezinski","year":"2015","unstructured":"Brezinski EA, Dhillon JS, Armstrong AW. Economic burden of psoriasis in the United States: a systematic review. JAMA Dermatol. 2015;151(6):651\u20138.","journal-title":"JAMA Dermatol"},{"issue":"6","key":"1240_CR4","doi-asserted-by":"publisher","first-page":"383","DOI":"10.2165\/00128071-200506060-00005","volume":"6","author":"AB Kimball","year":"2005","unstructured":"Kimball AB, et al. The psychosocial burden of psoriasis. Am J Clin Dermatol. 2005;6(6):383\u201392.","journal-title":"Am J Clin Dermatol"},{"issue":"1","key":"1240_CR5","doi-asserted-by":"publisher","first-page":"782","DOI":"10.1080\/13696998.2021.1937187","volume":"24","author":"J Bagel","year":"2021","unstructured":"Bagel J, et al. Dose escalation and associated costs in biologic treatment of psoriasis based on real-world data. J Med Econ. 2021;24(1):782\u201391.","journal-title":"J Med Econ"},{"issue":"10","key":"1240_CR6","first-page":"874","volume":"21","author":"SR Feldman","year":"2015","unstructured":"Feldman SR, et al. Economic and comorbidity burden among patients with moderate-to-severe psoriasis. J Manag Care Spec Pharm. 2015;21(10):874\u201388.","journal-title":"J Manag Care Spec Pharm"},{"issue":"4","key":"1240_CR7","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/j.ijwd.2016.09.003","volume":"2","author":"KT Shahwan","year":"2016","unstructured":"Shahwan KT, Kimball AB. Managing the dose escalation of biologics in an era of cost containment: the need for a rational strategy. Int J Womens Dermatol. 2016;2(4):151\u20133.","journal-title":"Int J Womens Dermatol."},{"issue":"9993","key":"1240_CR8","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1016\/S0140-6736(15)60125-8","volume":"386","author":"CE Griffiths","year":"2015","unstructured":"Griffiths CE, et al. Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials. Lancet. 2015;386(9993):541\u201351.","journal-title":"Lancet"},{"issue":"1","key":"1240_CR9","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.dsi.2016.09.005","volume":"35","author":"T-S Wang","year":"2017","unstructured":"Wang T-S, et al. Secukinumab in psoriasis patients with prior ustekinumab treatment: results of a single-center experience. Dermatol Sin. 2017;35(1):25\u20139.","journal-title":"Dermatol Sin"},{"issue":"12","key":"1240_CR10","first-page":"1366","volume":"25","author":"A Blauvelt","year":"2019","unstructured":"Blauvelt A, et al. Comparison of health care costs among patients with psoriasis initiating ixekizumab, secukinumab, or adalimumab. J Manag Care Spec Pharm. 2019;25(12):1366\u201376.","journal-title":"J Manag Care Spec Pharm"},{"key":"1240_CR11","unstructured":"Leigh Hansen. IBM MarketScan Research Databases for life sciences researchers. April 2018. https:\/\/www.ibm.com\/downloads\/cas\/0NKLE57Y. Accessed 15 May 2021."},{"key":"1240_CR12","unstructured":"Reiner Banken, Foluso Agboola, Katherine Fazioli, et al. Institute for Clinical and Economic Review. Targeted immunomodulators for the treatment of moderate-to-severe plaque psoriasis: effectiveness and value. June 12, 2018. https:\/\/icer.org\/wp-content\/uploads\/2020\/10\/ICER_Psoriasis_Update_Evidence_Report_061218.pdf. Accessed 15 May 2021."},{"issue":"3","key":"1240_CR13","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1080\/00273171.2011.568786","volume":"46","author":"PC Austin","year":"2011","unstructured":"Austin PC. An introduction to propensity score methods for reducing the effects of confounding in observational studies. Multivariate Behav Res. 2011;46(3):399\u2013424.","journal-title":"Multivariate Behav Res."},{"issue":"1","key":"1240_CR14","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1080\/09546634.2019.1690622","volume":"32","author":"MJ Murage","year":"2021","unstructured":"Murage MJ, et al. Ixekizumab treatment patterns and healthcare utilization and costs for patients with psoriasis. J Dermatol Treat. 2021;32(1):56\u201363.","journal-title":"J Dermatol Treat"},{"issue":"3","key":"1240_CR15","first-page":"201","volume":"21","author":"SR Feldman","year":"2015","unstructured":"Feldman SR, et al. Patterns of medication utilization and costs associated with the use of etanercept, adalimumab, and ustekinumab in the management of moderate-to-severe psoriasis. J Manag Care Spec Pharm. 2015;21(3):201\u20139.","journal-title":"J Manag Care Spec Pharm"},{"issue":"4","key":"1240_CR16","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0033486","volume":"7","author":"EA Brezinski","year":"2012","unstructured":"Brezinski EA, Armstrong AW. Off-label biologic regimens in psoriasis: a systematic review of efficacy and safety of dose escalation, reduction, and interrupted biologic therapy. PLoS ONE. 2012;7(4): e33486.","journal-title":"PLoS ONE"},{"issue":"4","key":"1240_CR17","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1080\/09546634.2018.1524820","volume":"30","author":"A Bewley","year":"2019","unstructured":"Bewley A, et al. Dose increase beyond labelled dose of biologics is associated with incremental pharmacy costs: results from a real-world study in the UK. J Dermatol Treat. 2019;30(4):376\u201382.","journal-title":"J Dermatol Treat"},{"issue":"8","key":"1240_CR18","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1080\/13696998.2018.1472097","volume":"21","author":"MJ Murage","year":"2018","unstructured":"Murage MJ, et al. Healthcare resource utilization and costs among psoriasis patients treated with biologics, overall and by disease severity. J Med Econ. 2018;21(8):745\u201354.","journal-title":"J Med Econ"},{"issue":"12","key":"1240_CR19","doi-asserted-by":"publisher","first-page":"1224","DOI":"10.1080\/13696998.2017.1362413","volume":"20","author":"S Al Sawah","year":"2017","unstructured":"Al Sawah S, et al. Cost per additional responder for ixekizumab and other FDA-approved biologics in moderate-to-severe plaque psoriasis. J Med Econ. 2017;20(12):1224\u201330.","journal-title":"J Med Econ"}],"container-title":["Clinical Drug Investigation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-022-01240-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40261-022-01240-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-022-01240-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,14]],"date-time":"2023-03-14T02:16:16Z","timestamp":1678760176000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40261-022-01240-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,25]]},"references-count":19,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,3]]}},"alternative-id":["1240"],"URL":"https:\/\/doi.org\/10.1007\/s40261-022-01240-9","relation":{},"ISSN":["1173-2563","1179-1918"],"issn-type":[{"type":"print","value":"1173-2563"},{"type":"electronic","value":"1179-1918"}],"subject":[],"published":{"date-parts":[[2023,2,25]]},"assertion":[{"value":"20 December 2022","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 February 2023","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was funded by Eli Lilly and Company.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Andrew Blauvelt has served as a scientific adviser and\/or clinical study investigator for AbbVie, Abcentra, Aligos, Almirall, Amgen, Arcutis, Arena, Aslan, Athenex, Boehringer Ingelheim, Bristol-Myers Squibb, Dermavant, EcoR1, Eli Lilly and Company, Evommune, Forte, Galderma, Incyte, Janssen, Landos, Leo, Novartis, Pfizer, Rapt, Regeneron, Sanofi Genzyme, Sun Pharma, UCB Pharma, and Vibliome. Nianwen Shi, Carolyn R. Lew, and Nicole M. Zimmerman are employees of IBM Watson Health who were compensated by Eli Lilly and Company for conducting this research. Najwa Somani, Scott A. Kern, Russel Burge, Terri Ridenour, Baojin Zhu, and Mwangi Murage are full-time employees and stockholders of Eli Lilly and Company.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Data for these analyses are derived from the IBM MarketScan<sup>\u00ae<\/sup> Research Databases. The data are not publicly available because of data use agreements and can be accessed by purchasing a license through IBM Watson Health. Interested individuals may visit  for more information on accessing the MarketScan<sup>\u00ae<\/sup> Research Databases.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"NS had full access to all the data in the study and was responsible for the integrity of the data and the accuracy of data analysis. AB, NS, RB, BZ, and MJM were involved in the conception and design of the study. AB, NS, RB, CRL, NMZ, SAK, BZ, and MJM acquired, analyzed, or interpreted the data. AB, NS, RB, CRL, NMZ, BZ, SAK, and MJM contributed towards the critical revision of the manuscript for important intellectual content. NMZ conducted the statistical analysis. The manuscript was drafted under the supervision of MJM and NS. All authors contributed to the data analysis, drafting, and revising the article, gave final approval of the version to be published, and agree to be accountable for all aspects of the work.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}}]}}